ED-B fibronectin as a target for antibody-based cancer treatments

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.9, Iss.3, 2005-06, pp. : 491-500

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antibodies to the ED-B domain of fibronectin, their constructs and uses

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 7, 1998-07 ,pp. : 907-910

Informa Healthcare

Access to resources Recommend Favorite

Antibody-based cancer therapy

By Baxevanis Constantin N

Expert Opinion on Drug Discovery, Vol. 3, Iss. 4, 2008-04 ,pp. : 441-452

Informa Healthcare

Access to resources Recommend Favorite

Antibody-based antiangiogenic cancer therapy

By Sanz Laura Álvarez-Vallina Luis

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 6, 2005-12 ,pp. : 1235-1245

Informa Healthcare

Access to resources Recommend Favorite

uPAR as Anti-Cancer Target: Evaluation of Biomarker Potential, Histological Localization, and Antibody-Based Therapy

Current Drug Targets, Vol. 12, Iss. 12, 2011-11 ,pp. : 1744-1760

Bentham Science Publishers

Access to resources Recommend Favorite

Development and prospects for bispecific antibody-based therapeutics in cancer and other applications

By Lum Lawrence G Al-Kadhimi Zaid

Expert Opinion on Drug Discovery, Vol. 3, Iss. 9, 2008-09 ,pp. : 1081-1097

Informa Healthcare

Access to resources Recommend Favorite